ACO2 antibody (AA 651-750)
Quick Overview for ACO2 antibody (AA 651-750) (ABIN739590)
Target
See all ACO2 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 651-750
-
Predicted Reactivity
- Human,Mouse,Rat,Dog,Cow,Pig,Horse,Rabbit
-
Purification
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human Aconitase 2
-
Isotype
- IgG
-
-
-
-
Application Notes
-
WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
-
Expiry Date
- 12 months
-
-
- ACO2 (Aconitase 2, Mitochondrial (ACO2))
-
Alternative Name
- Aconitase 2
-
Background
-
Synonyms: ACO 2, ACO2, aconitase 2, Aconitase 2 mitochondrial, Aconitase, Aconitase2, Aconitate hydratase, Aconitate hydratase mitochondrial, ACONM, Citrate hydro lyase.
Background: ACO2, also referred to as aconitate hydratase, citrate hydrolyase or aconitase, is an iron-sulfur hydrolyase that catalyzes the non-limiting interconversion of citrate and isocitrate in the tricarboxylic acid cycle. It is expressed in the mitochondria and maintains a citrate:isocitrate ratio of approximately 10:1. ACO2 contains a redox-sensitive iron-sulfur cluster that exists in two states: active (Fe4S4) and inactive (Fe3S4). ACO2 activity is dependent on the state of this cluster as well as the presence of two conserved cysteine residues. In normal prostate epithelial cells ACO2 activity is prevented due to the high levels of zinc inhibiting the enzyme. In these citrate-producing epithelial cells citrate oxidation is impaired allowing citrate to accumulate and exhibit a citrate:isocitrate ratio of approximately 30:1. In malignant prostate cells zinc is unable to accumulate, therefore ACO2 activity resumes and citrate is oxidized.
-
Gene ID
- 50
Target
-